T. Rowe Price Investment Management’s Stoke Therapeutics STOK Stock Holding History

T. Rowe Price Investment Management’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.17M	Buy	+250,913	New	+$8.23M	0.01%	544

Other funds holding STOK

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

T. Rowe Price Investment Management's STOK Position: Q1 2026 in Review

T. Rowe Price Investment Management opened a new position in Stoke Therapeutics (STOK) in Q1 2026: 250,913 shares worth $8.17M. The stake represents 0.01% of the portfolio and ranks #544 among its holdings.

197 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

T. Rowe Price Investment Management held 250,913 shares of Stoke Therapeutics worth $8.17M as of Q1 2026.
Stoke Therapeutics was a new T. Rowe Price Investment Management position in Q1 2026.
Stoke Therapeutics made up 0.01% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #544 holding.
197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.